key: cord-0290779-fn60b0f6
authors: Chang, A. Y.; Aaby, P.; Avidan, M. S.; Benn, C. S.; Bertozzi, S. M.; Blatt, L.; Chumakov, K.; Khader, S. A.; Kottilil, S.; Nekkar, M.; Netea, M. G.; Sparrow, A.; Jamison, D. T.
title: One vaccine to counter many diseases? Modelling the economics of oral polio vaccine against child mortality and COVID-19
date: 2022-01-21
journal: nan
DOI: 10.1101/2022.01.19.22269560
sha: 99456656620cb527cd890da76b4dd3de18679630
doc_id: 290779
cord_uid: fn60b0f6

Background: Recent reviews summarize evidence that some vaccines have heterologous or non-specific effects (NSE), potentially offering protection against multiple pathogens. Numerous economic evaluations examine vaccines' pathogen-specific effects, but we have found only two economic evaluations of NSE. This paper starts to fill this gap by reporting economic evaluations of the NSE of oral polio vaccine (OPV) against under-five mortality and COVID-19. Methods: We studied two settings: (1) reducing child mortality in a high-mortality setting (Guinea-Bissau) and (2) preventing COVID-19 in India. In the former, the intervention involves three annual campaigns in which children receive OPV incremental to routine immunization. In the latter, a susceptible-exposed-infectious-recovered model was developed to estimate the population benefits of two scenarios, in which OPV would be co-administered alongside COVID-19 vaccines. Incremental cost-effectiveness and benefit-cost ratios were modelled for ranges of intervention effectiveness estimates to supplement the headline numbers and account for heterogeneity and uncertainty. Results: For child mortality, headline cost-effectiveness was $650 per child death averted. For COVID-19, assuming OPV had 20% effectiveness, incremental cost per death averted was $23,000-65,000 if it were administered simultaneously with a COVID-19 vaccine less than 200 days into a wave of the epidemic. If the COVID-19 vaccine availability were delayed, the cost per averted death would decrease to $2600-6100. Estimated benefit-to-cost ratios vary but are consistently high. Conclusion: Economic evaluation suggests the potential of OPV to efficiently reduce child mortality in high mortality environments. Likewise, within a broad range of assumed effect sizes OPV could play an economically attractive role against COVID-19.

intervention involves three annual campaigns in which children receive OPV 48 incremental to routine immunization. In the latter, a susceptible-exposed-infectious-49 recovered model was developed to estimate the population benefits of two scenarios, 50 in which OPV would be co-administered alongside COVID-19 vaccines. Incremental 51 cost-effectiveness and benefit-cost ratios were modelled for ranges of intervention 52 effectiveness estimates to supplement the headline numbers and account for 53 heterogeneity and uncertainty. dosage each year for three consecutive years, compared to a hypothetical cohort 142 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in and standardized sensitivity analyses were undertaken in accordance with current 160 guidelines (appendix p4).(21) Furthermore, since the intervention population is young 161 children, we reduced the VSL by 50% to account for the fact that in some literature a 162 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The first wave of the COVID-19 epidemic among adults in India was selected to 179 illustrate the potential use of OPV during a pandemic wave. India was chosen because 180 it has national seroprevalence surveys and faced delays in immunizing a large 181

proportion of the population with the COVID-19 vaccine. Following the national 182 surveys, we set the first day of the simulation to mid-May 2020, when 0.7% of the 183 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.19.22269560 doi: medRxiv preprint population was estimated to be sero-positive and set 25% of them as the initial exposed were studied (Table 1 and appendix p15). In both scenarios, the COVID-19 vaccine is 196 introduced with a long implementation delay to reflect the time required to develop, 197 test, approve, manufacture, procure, and administer. It also has a lag time between 198 when the vaccine is administered and when it achieves full effect (about 3-5 weeks). 199

In the first scenario, both vaccines are simultaneously administered on the same day, 200 t days after the beginning of an epidemic wave. OPV is used to cover the 3-5 weeks 201 before the COVID-19 vaccine achieves full effectiveness. In the second scenario, 202 individuals expected to receive the COVID-19 vaccine will first receive OPV at day t,

and then receive the COVID-19 vaccine d days after OPV administration (i.e., t+d 204 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in For both settings, given the heterogeneity and uncertainty surrounding several input 239 parameters, we ran a thorough set of sensitivity analyses for model inputs related to 240 the epidemic (baseline mortality and severity parameters, basic reproduction number 241 (R0), infectiousness ratio between symptomatic and asymptomatic individuals), 242 vaccine (coverage, delay, effectiveness against infections, infectivity, severity), cost 243 (vaccine, campaign, wastage), and VSL (GNI per capita) (appendix pp 5-6 and pp 24-244 33). 245 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The main results are presented in Table 2 incremental cost-effectiveness of $3500-6100 per death averted and a benefit-to-cost 296 ratio in the range of 60-110. Results for higher OPV effectiveness (60%) and vaccine 297 coverage (50%) are presented in Table 2 and appendix pp 20-21. 298 299 Sensitivity analysis

The full results from the sensitivity analyses are presented in the appendix. In setting 301 1, the model is most sensitive to plausible variations in baseline mortality, OPV 302 effectiveness, campaign delivery cost, and GNI per capita (appendix p6; Figure 2 shows 303 the results for plausible ranges of mortality and effectiveness). In setting 2, the model 304 is most sensitive to variations in some of the underlying epidemic parameters, vaccines' 305 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in LAV, found that BCG revaccination decreased COVID-19 risk by 68% among the 322 older adults, whereas a press release from another randomized trial testing a primary 323 dose of BCG among older adults reported no effect on COVID-19 incidence.(14,30) 324

Biologically and epidemiologically plausible evidence suggest that there may be a 325 beneficial effect of OPV in relation to COVID-19.(9,31) We therefore applied a wide 326 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The model was calibrated against data from India's first wave as an illustration and 339 we by no means aimed to accurately project the actual epidemic. India's first wave 340 was also relatively mild in comparison to other countries (appendix p13), so the 341 estimated health impacts are likely conservative. Similarly, income levels, vaccine and 342 delivery costs will lead to differences in benefit-cost and cost-effectiveness ratios. In 343 the child mortality analysis, we applied the mortality rates and effect sizes from studies 344 conducted in Guinea-Bissau, and these assumptions may not be applicable in other 345 settings, such as environments with much lower mortality, higher income and costs, 346 or with different vaccine schedules. 347 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Table 3 . More comprehensive analyses will include one or more of 365 these additional modes of use. 366 367 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.19.22269560 doi: medRxiv preprint

In the child mortality setting, we found that a 9.5% campaign effectiveness against 368 child mortality results in cost-effectiveness and benefit-cost ratios of $650 and 170 per 369 averted death. To put these numbers in perspective, previous studies found the cost-370 effectiveness ratio of national immunization programs to be in the order of $300-1800 371 per averted death.(34) GAVI, the Vaccine Alliance, estimated the benefit-cost ratio 372 for ten antigens to be around 50-70 by 2030.

(2) Even with lower OPV campaign 373 effectiveness, for example, 5-10% against child mortality, the cost-effectiveness and 374 benefit-cost ratios per averted death are economically attractive relative to other 375 interventions ( Figure 1 ). Deaths averted per thousand vaccinated was estimated at 2 376 per campaign dose (or 6 per vaccinated child), which is comparable to a recent study 377 that estimated deaths averted per thousand vaccinated across ten antigens to be 3.5 378 in 98 countries.(1) It is important to note that mortality reduction is additive to, not 379 a substitute for, mortality reduction in the standard immunization schedule. 380

In the COVID-19 setting, co-administering OPV alongside the COVID-19 vaccine 382 yielded favorable economic results. Applying OPV for bridge use becomes more 383 attractive with longer COVID-19 vaccine delays, shorter OPV delay, and higher OPV 384 effectiveness against the disease (Figures 2,3) . In line with other studies, we found that perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in approximates gradual coverage growth centered on those days. 4 5 6

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The results reflect the scenario in which vaccine coverage for both vaccines are set at 30%. The COVID-19 vaccine is assumed to be 74% effective against infections and reducing infectivity, 95% effective against severity, and require 28 days from administration until the it becomes fully effective. 95% uncertainty ranges are presented in appendix pp 20-21. DATI = deaths averted per thousand immunized; C/E = cost-effectiveness ratio; B/C = benefit-cost ratio; e = effectiveness of OPV vaccine against COVID-19. * Based on India's first wave of COVID-19. The results reflect the scenario in which vaccine coverage for both vaccines are set at 30%. OPV is administered simultaneously with the COVID-19 vaccine on day t. The COVID-19 vaccine is assumed to be 74% effective against infections and reducing infectivity, 95% effective against severity, and require 28 days from administration until the it becomes fully effective. e = effectiveness of OPV vaccine against COVID-19. The results reflect the scenario in which vaccine coverage for both vaccines are set at 30%. OPV is administered on day t, and the COVID-19 vaccine is administered d days after OPV. The COVID-19 vaccine is assumed to be 74% effective against infections and reducing infectivity, 95% effective against severity, and require 28 days from administration until the it becomes fully effective. e = effectiveness of OPV vaccine against COVID-19.

Estimating the health impact of vaccination against ten pathogens in 98 low-income 412 and middle-income countries from 2000 to 2030: a modelling study

Return On Investment From 415 Immunization Against 10 Pathogens In 94 Low-And Middle-Income Countries, 2011-416 30. Health Aff (Millwood)

Can existing live vaccines prevent 418 COVID-19? Science

BCG-induced 420 non-specific effects on heterologous infectious disease in Ugandan neonates: an 421 investigator-blind randomised controlled trial

Cost-424 effectiveness of providing measles vaccination to all children in Guinea-Bissau. Glob 425 Health Action

A Health Economic Analysis for Oral 427

Poliovirus Vaccine to Prevent COVID-19 in the United States

Potential use of nonpathogenic enteroviruses for control of human 430 disease

Stopping Oral 432 Polio Vaccine (OPV) after Defeating Poliomyelitis: A Pyrrhic Victory? Systematic 433 Review of the Non-Specific Effects of OPV

Social Science 434 Research Network

Old vaccines 437 for new infections: Exploiting innate immunity to control COVID-19 and prevent 438 future pandemics

Coronavirus Pandemic (COVID-19)

Efficacy of the 446 ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Outcomes Worldwide Network for CORONAvirus prevenTION

ACTIVATE-2: A DOUBLE-BLIND RANDOMIZED TRIAL OF BCG 453 VACCINATION AGAINST COVID19 IN INDIVIDUALS AT RISK

Oral Polio Vaccine as Potential Protection Against 456 COVID-19: A Cluster-randomised Trial in Guinea-Bissau

Russia's Chumakov Center proves efficacy of polio vaccine 460 against Covid-19

National 463 immunisation campaigns with oral polio vaccine may reduce all-cause mortality: An 464 analysis of 13 years of demographic surveillance data from an urban African area

Analysis 467 of risk factors for infant mortality in the 1992-3 and 2002-3 birth cohorts in rural 468 Guinea-Bissau

UNICEF Supply Division. UNICEF Oral polio vaccine (OPV) price data.pdf

Vaccine wastage in 473 The Gambia: a prospective observational study

Note on Panel C: The benefit-to-cost ratio (B/C) is the ratio of the dollar value of benefits to the dollar value of costs

We would like to acknowledge Drs. Robert Gallo, Walter Orenstein, Kelly Sanders, 539 Jaime Sepulveda, Kimberly Thompson, and Damian Walker for their scientific inputs. 540Conclusions and views expressed in the paper are those of the authors alone.